Monness, Crespi, Hardt maintains a 'Buy' on Innospec (IOSP); Becoming a Significant Takeover Target

Monness, Crespi, Hardt maintains a 'Buy' on Innospec (NASDAQ: IOSP) price target of $40.00.

Analyst, Chris Shaw, feels IOSP is a significant takeover target considering the company's recent removal of its poison pill, along with inexpensive valuation and positive market position in fuel additives...Shaw's potential suitors include NewMarket Corp. (NYSE: NEU), Chemtura Corp. (Nasdaq: CHMT), Albemarle (NYSE: ALB) or Berkshire Hathaway's (NYSE: BRK-A) Lubrizol.

Also worth noting, Shaw expects a floor of ~$30/share as IOSP becomes more active in buying back stock.

For an analyst ratings summary and ratings history on Innospec click here. For more ratings news on Innospec click here.

Shares of Innospec closed at $29.83 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Bernstein on whether Hershey (HSY) could eventually step up to buy Mondelez (MDLZ)
• MicroCloud Hologram acquires 140,268 MicroStrategy shares via structured note
• Deere (DE) PT Raised to $585 at JPMorgan